MODERNA
His grandfather died of pancreatic cancer: This Hyderabad startup founder is using AI to develop a personalised cancer vaccines
Hyderabad-based biotech startup PopVax, founded by Soham Sankaran, is developing AI-powered personalised cancer vaccines using mRNA technology. Inspired partly by his family's experience with pancreatic cancer, he aims to help the immune system identify and attack cancer cells using treatments designed around individual patients' tumour genetics.
Dolly Parton’s father inspired her to help millions of children read; her foundation has gifted over 330 million books
Dolly Parton's philanthropy was deeply influenced by her childhood experiences and her father's struggles with literacy. She established the Imagination Library in 1995 to promote reading among children, providing over 330 million books. Her educational initiatives also targeted high school graduation rates, significantly decreasing local dropout rates. Parton contributed to disaster relief efforts after wildfires in Tennessee and funded COVID-19 vaccine research.
Dragon enters bear cave with $2.4 trillion lost since May peak
Chinese stocks have recently entered a bear market, resulting in a total loss of $2.4 trillion. Major indexes, including the CSI 300 and Hang Seng, have significantly declined in value. Investors express concerns about the future profitability of artificial intelligence companies and weak domestic demand. Analysts suggest the market malaise may continue into next year without substantial policy changes.
Moderna stock crashes 25%, loses about $24 billion after cancer vaccine data leak
Moderna’s stock price dropped over 25% after trial results for its personalized melanoma vaccine with Merck were disclosed. The decline erased approximately $24 billion from Moderna’s market value, ending a significant rally this year. Analysts noted that this reaction was expected as investors often sell after news becomes public. Despite the drop, the trial results showed promising reductions in cancer recurrence when paired with Merck's Keytruda.
US stocks 2026: Moderna, SanDisk lead top 10 gainers delivering up to 734% returns
Ten US stocks with market caps above $5 billion have seen share prices more than triple in 2026, delivering returns up to 734%. Healthcare and tech sectors dominate, led by biotechnology firm Moderna and flash memory maker SanDisk, highlighting strong momentum across biotech and established tech majors like Dell.
US stocks today: US stocks end higher as healthcare stocks lift Dow, tech a breather
Wall Street ended higher on Tuesday, led by the Dow as investors shifted towards healthcare and other value stocks. The S&P 500 also gained, while the Nasdaq slipped as technology stocks paused after a rebound in the previous session. Healthcare shares gained, while small-caps and defensive sectors also outperformed.
- Go To Page 1
Dolly Parton started a foundation in 1995 to help young children read. Donated nearly 325 million books across the US, UK, and Canada; her father's inability inspired her
Dolly Parton, who passed away on August 25, 2026, left behind a significant philanthropic legacy. The Imagination Library, launched in 1995, has gifted over 325 million books to young children. This initiative started from her own father's literacy challenges and aimed to improve access to books. Furthermore, Parton contributed to healthcare and disaster relief, reflecting her commitment to service. Her work continues to influence children's literacy and community support.
We are working to develop relations with China once again: Piyush Goyal
Commerce and Industry Minister Piyush Goyal stated that India seeks to improve relations with China, ensuring fair deals. Bilateral trade between India and China reached USD 127.7 billion, which reflects significant growth in exports and imports. Furthermore, Goyal expressed concerns regarding the widening trade deficit and tightened FDI policies due to geopolitical tensions. India experienced supply chain vulnerabilities during Covid, leading to a focus on self-sufficiency.
US stocks: Nasdaq rises while S&P, Dow dip as softer inflation cools Fed hike bets
On Wednesday, inflation data led to mixed market movements, with the Nasdaq increasing slightly. The Dow and S&P 500 faced declines, although both indexes posted quarterly gains. Private employers added 90,000 jobs in September, contributing to labor market reports this week. The S&P 500 achieved new highs while also experiencing several lows in its performance. Rising concerns about inflation continue to influence economic outlooks and Federal Reserve expectations.
US stocks: US market rises as cooler inflation data ease October Fed hike bets
U.S. stocks surged higher as inflation reports came in softer than analysts predicted, easing worries about potential interest rate hikes. The Commerce Department revealed a 3.4% increase in the Personal Consumption Expenditures price index year-over-year. Major players like Apple and Alphabet enjoyed price rises, contributing to a notable boost in the Nasdaq Composite.
Vivek Ramaswamy is worth $2.3bn. A win in Ohio could make him America’s second-richest governor
Vivek Ramaswamy's fortune has significantly increased due to Roivant Sciences' stock performance. He has sold billions in company stock over the past year. This growing wealth contrasts with his opponent's campaign message. Ramaswamy's stake in Roivant has decreased, but he holds other investments. His financial success is a key point on the Ohio campaign trail.
Moderna, Merck breakthrough could usher in wave of cancer vaccines
Merck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target specific tumor mutations. The vaccine, combined with Keytruda, significantly reduced cancer recurrence in trials. Doctors are hopeful this approach will expand to treat many other cancer types. Further trials are underway for lung, bladder, kidney, pancreatic, and stomach cancers.
US stocks: US market rises as yields ease, Moderna lifts healthcare stocks
US stock markets enjoyed a boost as easing bond yields and a spike in Moderna shares contributed to a favorable trading environment. Despite the Federal Reserve's minutes highlighting inflation concerns and discussions on rate hikes, investors remained optimistic. The Treasury's announcement of liquidity support revitalized riskier assets, particularly in tech stocks, while the success of Moderna's cancer therapy trial uplifted the healthcare sector.
Moderna shares soar 159% in a day after cancer vaccine succeeds in late-stage trial
Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings offer hope for future growth beyond COVID-19 vaccines. Discussions with regulators are expected within the next few months.
US Stocks: Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang
Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing it to focus on its pipeline.
Moderna layoffs: U.S. Pharma giant announces massive job cuts, to have less than 5,000 employees, MRNA stocks sink
Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. MRNA stock, which has lost more than 90 per cent of its value since the pandemic-era highs, was trading about 4 per cent down on Thursday.
Moderna open to supplying COVID vaccines to China, CEO says
"We are open, we have the capacity" Bancel said about supplying its mRNA-based shots to the country, declining to say whether Moderna had submitted its vaccine for approval there.
Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine
Moderna alleges Pfizer/BioNTech, without permission, copied mRNA technology that Moderna had patented between 2010 and 2016, well before COVID-19 emerged in 2019 and exploded into global consciousness in early 2020. Moderna has also been sued for patent infringement in the United States and has an ongoing dispute with the U.S. National Institutes of Health over rights to mRNA technology.
Moderna says its low-dose COVID shots work for kids under 6
Moderna's COVID-19 vaccine works in babies, toddlers and preschoolers the company announced -- and if regulators agree it could mean a chance to finally start vaccinating the littlest kids by summer.
Moderna finds that inventing a COVID-19 vaccine was the easy part
Moderna shares plummeted on Thursday after it announced it would be able to supply only 700 million to 800 million vaccine doses this year, down from its previous projection of 800 million to 1 billion doses. It attributed the lower forecast not to any complications in making the mRNA itself, an issue it dealt with earlier this year, but to delays in filling vials and delivering them in international markets.
Moderna vaccine to be available at select hospitals by Mid-July
Last week, Indian’s drug regulator granted permission to Cipla to import donated doses of Moderna from the US. The vax doses, which are being imported by Cipla, will be given to the central government and will be available in select metros which have hospitals where the vaccine can be stored easily, the same people said.
Moderna anticipates its COVID-19 vaccine to safeguard against new mutated coronavirus
"Moderna expects that the immunity induced by its COVID-19 vaccine would be protective against coronavirus variants reported in the United Kingdom (UK)," read the statement released by Moderna.
Load More
